EVIDENCE. COMPARISONS. CLEAR NEXT STEPS.FOR US CLINIC TEAMS PROCUREMENT RESEARCH
Next steps

Stage 6: How should you pilot and transition without losing control?

Dose Diligence research deskSection 12 · Page 7 of 11Last updated 17 Nov 2026

Prove the full patient-access workflow before increasing dependence on the partner. Use a clinically appropriate, limited cohort spanning the states, presentations and payment routes that matter to the proposed rollout.

A pilot should cover initial dispensing and a refill interaction where applicable. Its duration should follow the workflow being tested, rather than an arbitrary calendar deadline.

Before the pilot

  • Approve the route and facility-state matrix.
  • Test routing, acknowledgements, status updates and exception handling with synthetic data first.
  • Agree patient-facing pricing, payment, shipping and support communications.
  • Assign clinical ownership of any medicine, dose or presentation change.
  • Set written acceptance thresholds using your baseline and negotiated requirements.
  • Confirm a usable fallback, including intake requirements and available capacity.

During the pilot

Track prescription acceptance, missing-information requests, payment completion, dispensing, delivery, exceptions, refunds and refill readiness. Record both elapsed time and the reason for each delay.

A practical branded-route detail: LillyDirect’s provider FAQ says dose or format corrections require a new prescription. Include this handoff in testing rather than assuming operations staff or the dispensing pharmacy can amend the original instruction. (lilly.com)

Before moving existing patients

  • Reconcile outstanding prescriptions, authorisations, payments and shipments.
  • Decide which prescriptions require transfer, renewal or replacement through the appropriate clinical/pharmacy process.
  • Check for duplicate orders and charges across old and new routes.
  • Give patients clear instructions about the new pharmacy, payment and support contacts.
  • Have clinicians review patients whose access interruption or presentation change needs individual attention.
  • Keep an owner for unresolved orders after the formal cutover.

Stop expansion for unresolved identity, permission, provenance or serious quality concerns, or when the agreed operational acceptance criteria are not met. Correct the problem and repeat the affected test before scaling.

Exit test: operations and clinical leadership jointly approve the results, finance verifies actual charges, and the fallback has been tested rather than merely named.

Sources cited on this page

  1. lilly.com · Source 1 ↗https://www.lilly.com/lillydirect/hcp/faq
Section sources →